Impact of Inflammatory Bowel Disease and Azathioprine on Long‐Term Outcomes After Liver Transplantation for Primary Sclerosing Cholangitis
| Autor: | Sarang Paleri, Matthew Peverelle, Paul J Gow, Peter De Cruz |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Transplantation
medicine.medical_specialty endocrine system diseases Hepatology business.industry medicine.medical_treatment digestive oral and skin physiology Retrospective cohort study Azathioprine Liver transplantation medicine.disease Malignancy digestive system Inflammatory bowel disease Gastroenterology digestive system diseases Primary sclerosing cholangitis Internal medicine Long term outcomes Medicine Surgery business medicine.drug |
| Zdroj: | Liver Transplantation. 27:770-771 |
| ISSN: | 1527-6473 1527-6465 |
| DOI: | 10.1002/lt.26009 |
| Popis: | We read with interest the multicentre retrospective study by Irles-Depe et al1 reporting the impact of inflammatory bowel disease (IBD) on long-term outcomes after liver transplantation (LT) for primary sclerosing cholangitis (PSC). In their series PSC-IBD patients were found to have similar rates of death, recurrent PSC (rPSC) and malignancy as patients with isolated PSC. Moreover azathioprine (AZA) exposure was associated with increased mortality, an association which may have been due to an era effect. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text